International Stem Cell Corporation (ISCO) Stock Price & Analysis
International Stem Cell Corporation (ISCO) — price $0.16 (+10.34%), as of the Nov 19, 2026 trading session; market cap $1.28M.
Educational signal · not a buy or sell recommendation · How to read this
International Stem Cell Corporation · ISCO
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm focused on developing therapeutic and biomedical solutions derived from proprietary human parthenogenetic stem cells. The company also commercializes anti-aging skincare products and human cell culture products for research across various scientific disciplines.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.16 | |
| Change on the day | +10.34% | |
| 52-week range | $0.117 – $0.54 | |
| Market capitalisation | $1.28M | — |
| Shares traded on the day | 16.8K |
Price & events
Other perspectives
Council score for International Stem Cell (ISCO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is International Stem Cell (ISCO), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. International Stem Cell Corporation (ISCO) is the company analyzed here. It employs 33 people and is led by Andrey Semechkin. In Q2 FY2026 it reported revenue of $3M and net income of -$71,000. The market values it at $1.28M.
What do the latest results show for International Stem Cell (ISCO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3M | -$71,000 | -$0.01 (diluted) |
| Q1 FY2026 | $2M | -$220,000 | -$0.03 (diluted) |
| Q4 FY2025 | $2M | -$348,000 | -$0.03 (diluted) |
| Q3 FY2025 | $2M | $57,000 | $0.01 (diluted) |
What are the financial strengths and risks for International Stem Cell (ISCO)?
Short answer · as of
The distress and quality screens read Altman Z -29.28 · Piotroski F 4. Trailing ratios: ROE 19.4% · ROA -11.5% · current ratio 0.79 · earnings yield -45.7% · free-cash-flow yield 26.2%.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 16, 2026
- Transactions
- 6
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 1
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ISCO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ISCO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: ISCO Stock
These answers are editorial: 1 of these 8 answers is drawn from the ISCO research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ISCO a good stock to buy?
Stock Expert AI does not rate ISCO buy, sell or hold. International Stem Cell Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ISCO stock price today?
The last price recorded for International Stem Cell Corporation (ISCO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What revenue streams does International Stem Cell Corporation have in healthcare and related markets?
International Stem Cell Corporation (ISCO) generates revenue through a diversified portfolio of products. A significant portion comes from its extensive range of human cell culture products, which include specialized cells, reagents, and supplements vital for research across dermatology, cardiovascular, oncology, respiratory, reproductive, urological, musculoskeletal, and metabolic disciplines.
What are the key factors to evaluate for ISCO?
Evaluate ISCO on fundamentals, analyst consensus, and risk factors. ISCO does not currently offer a dividend, with a Dividend Yield of None, aligning with its clinical-stage biotechnology focus on reinvesting earnings into growth. Not financial advice.
How frequently does ISCO data refresh on this page?
ISCO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ISCO's recent stock price performance?
International Stem Cell Corporation (ISCO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary human parthenogenetic stem cell technology provides a unique competitive advantage. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ISCO overvalued or undervalued right now?
International Stem Cell Corporation (ISCO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ISCO before investing?
Before investing in International Stem Cell Corporation (ISCO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com